|
|
|
|
Sun Pharma Announces USFDA Approval for Generic Prometh Syrup
Source : Sun Pharmaceuticals Industries Ltd Sun Pharma Announces USFDA Approval for Generic Prometh Syrup Sun Pharmaceutical Industries Ltd.(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that the USFDA has granted its subsidiary...
|
|
|
Sun Pharma bags FDA Approval for Prometh syrup
Sun Pharmaceutical announced that the USFDA has granted its subsidiary an approval for its ANDA for Promethazine Hydrochloride and Codeine Phosphate Oral Syrup, 6.25 mg/5 ml and 10mg/5ml.Sun Pharma bags FDA Approval for Prometh syrup.
|
|
|
Sun Pharma announces USFDA approval for generic Prometh Syrup
Mumbai: Sun Pharmaceutical Industries announced that the USFDA has granted its subsidiary an approval for its ANDA for Promethazine Hydrochloride and Codeine Phosphate Oral Syrup, 6.25 mg/5 ml and 10mg/5ml.This Promethazine Hydrochloride with...
|
|
|
Sun Pharma gets approval from USFDA for Prometh
Tags: Drug, Prometh syrup, Sun Pharma, USFDA, Companies Drug major Sun Pharma today said it has received approval from the US health regulator for generic version of anti-allergic product Prometh syrup.The United States Food and Drug Administration (FDA) has...
|
|
|
GLENMARK PHARMACEUTICALS LTD. - BONDS: PRESS RELEASE - GLENMARK GENERICS RECEIVES APPROVAL FROM USFDA FOR MOEXIPRIL HYDROCHLORIDE TABLETS
Miscellaneous* Asterisks denote mandatory informationName of Announcer *SINGAPOR GLENMARK PHARMACEUTICALS LTD.- BONDS: PRESS RELEASE - GLENMARK GENERICS RECEIVES APPROVAL FROM USFDA FOR MOEXIPRIL HYDROCHLORIDE TABLETS.
|
|
|
Watson Receives FDA Approval for Generic Cardizem(R) LA
Watson Pharmaceuticals announced that its subsidiary, Watson Laboratories, Inc.- Florida, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended...
|
|
|
Depression: Study findings from Sutcu Imam University, Department of Pharmacology broaden understanding of depression
Today's Medical & Research News Depression Study findings from Sutcu Imam University, Department of Pharmacology broaden understanding of depression March 17th, 2010 Printer-Friendly Version City:Kahramanmaras Country:Turkey Depression Antidepressant...
|
|
|
Mylan Announces First-to-File Opportunity Settlement Agreements for Actoplus Met(R) and Actos(R)
-- Mylan Inc.(Nasdaq: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met(), 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone ...
|
|
|
Watson Pharmaceuticals Inc awarded FDA approval for generic Cardizem LA
Pharmaceutical company Watson Pharmaceuticals Inc (NYSE:WPI) declared on Monday the receipt of approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release tablets for...
|
|
|
Watson Receives FDA Approval for Generic Cardizem(R) LA
MORRISTOWN, N.J., March 15 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc.(NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the U.S. Food and Drug Administration (FDA) for its...
|
|
|
Watson Receives FDA Approval for Generic Cardizem(R) LA
MORRISTOWN, N.J., March 15 /PRNewswire-FirstCall/ Watson Pharmaceuticals, Inc.(NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. Florida, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated...
|
|
|
3/15/10 - Watson Receives FDA Approval for Generic Cardizem(R) LA
MORRISTOWN, N.J., March 15 /PRNewswire-FirstCall/ Watson Pharmaceuticals, Inc.(NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. Florida, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated...
|
|
|
Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
JACKSONVILLE, Fla., March 15 /PRNewswire/ Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc.(collectively, 'Ranbaxy'), announced today that they have reached an agreement with Takeda Pharmaceutical Company...
|
|
|
Mylan Announces First-to-File Opportunity Settlement Agreements for Actoplus Met(R) and Actos(R)
Mylan Inc.(Nasdaq: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone ...
|
|
|
Mylan Announces First-to-File Opportunity Settlement Agreements for Actoplus Met(R) and Actos(R)
Mylan Inc.(Nasdaq: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone ...
|
|
|
Mylan Announces First-to-File Opportunity Settlement Agreements for Actoplus Met(R) and Actos(R)
Mylan Inc.(Nasdaq: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met(R), 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone ...
|
|
|
Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical
Mylan Inc.(Nasdaq: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone ...
|
|
|
Mylan (MYL) Settles with Takeda Pharma Regarding Two Type 2 Diabetes Treatments
Mylan Inc.(NASDAQ: MYL) today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co. related to two treatments for type 2 diabetes: Actoplus Met, 15 mg/500 mg and 15 mg/850 mg, known generically as Pioglitazone ...
|
|
|
Watson Pharmaceuticals Inc awarded FDA approval for generic Cardizem LA
The FDA approval was secured by the company's subsidiary, Watson Laboratories Inc -- Florida.Diltiazem Hydrochloride Extended-Release tablets are the generic equivalent to Biovail Laboratories International SRL's Cardizem LA product.ACardizem LA...
|
|
|
Emory University: Safety data favor norepinephrine over dopamine for shock
Today's Medical & Research News Emory University Safety data favor norepinephrine over dopamine for shock March 16th, 2010 Printer-Friendly Version Anaphylactic Reaction Anaphylactic Shock Anaphylaxis Anesthesiology Bacterial Infections Blood Pressure...
|
|
|
Watson Pharma Climbing After Hours on Generic Hypertension Drug A...
Company: Watson Pharmaceuticals, Inc.(WPI) 3/15/2010-Shares of Watson Pharmaceuticals (NYSE:WPI) are trading 1.3% higher to $40.82 after hours Monday after the company announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received...
|
|
|
Watson Receives FDA Approval for Generic Cardizem(R) LA
Companies mentioned in this article: Watson Pharmaceuticals, Inc.MORRISTOWN, N.J., March 15 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval...
|
|
|
Watson Pharma (WPI) Subsidiary Get NDA from U.S. FDA for Ditiazem Hydrochloride XR Tablets
Watson Pharmaceuticals, Inc.(NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. Florida, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem ...
|
|
|
Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
Companies mentioned in this article: Ranbaxy Laboratories Limited JACKSONVILLE, Fla., March 15 /PRNewswire/ -- Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc.(collectively, 'Ranbaxy'), announced today that...
|
|
|
Ranbaxy Announces Settlement Of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
Jacksonville, FL -- /PRNewswire/ -- Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc.(collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and...
|
